New Real-World Evidence Study on Cannabinoid-Based Transdermal Gel Begins

Avicanna and Santé Cannabis have announced the launch of a new real-world evidence study into the use of the RHO Phyto™ CBG Transdermal Gel Topical Product in treating musculoskeletal inflammation and pain. The study will enroll and follow 100 patients using the treatment over 3 months, with a 3 month follow-up. Participants will submit self-reported symptom data, which will be collected alongside demographic information and medical history.

According to Yahoo!, “The study will be conducted by Santé Cannabis, an independent medical cannabis clinic and research services provider. Santé Cannabis has developed a data collection platform and centred model in executing upon its role as a CRS and CRO. The prospective study is expected to launch in early Q1 2023.”

To read more, click here.

(Source: Yahoo!, December 14^th, 2022)